Research programme: oncology-targeted therapeutic antibodies - Amorfix Life Sciences/Emergent BioSolutions

Drug Profile

Research programme: oncology-targeted therapeutic antibodies - Amorfix Life Sciences/Emergent BioSolutions

Latest Information Update: 18 Dec 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Amorfix Life Sciences
  • Developer ProMIS Neurosciences
  • Class Antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Suspended Cancer

Most Recent Events

  • 08 Aug 2014 Suspended for Cancer in Canada (Parenteral)
  • 21 Feb 2014 Cangene Corporation has been acquired and merged into Emergent BioSolutions
  • 06 Dec 2012 Early research in Cancer in Canada (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top